Aobo Capital
奥博资本
Aobo Capital (奥博资本 / OrbiMed) is a healthcare-focused investment firm active across China and global markets. Per 5Y Capital and BlueRun Ventures deal announcements, it has led or co-led multiple biotech and medtech rounds in recent years: it led Zhitai Bio's (知泰生物) over-RMB-500-million Series C in early 2026 , and has been a repeat backer of Pulnovo Medical, including as an existing investor making follow-on commitments in the company's 2025 Series C and 2026 Series D . It also participated in Pulnovo's earlier funding rounds dating back to 2022 . The firm's investment pattern shows particular concentration in innovative medical devices and biotherapeutics, typically investing at growth stages alongside top-tier Chinese VC peers.
AI-generated — may contain errors, please verify.
Coverage
Pulnovo Medical Completes $100 Million Series D Round Led by Medtronic, with Gaorong Ventures Continuing to Invest
Medtronic and Pulnovo Medical have signed a commercial cooperation agreement.
5Y News | QLT Biotherapeutics Raises Over 500 Million RMB in Series C Funding
Zhitai Biotech Closes Over 500 Million Yuan Series C Round to Accelerate Core Clinical Pipeline Development
BlueRun Ventures Continues to Double Down as QLT Biotherapeutics Closes Over RMB 500 Million Series C Round | BlueRun Family
Accelerate core clinical pipeline development
5Y News｜Minghui Pharma Closes $131 Million Pre-IPO Round to Accelerate Pipeline Development and Global Expansion
Dedicated to developing innovative therapies that address unmet clinical needs worldwide.
Rongbao | Generative AI and medical device companies close new funding rounds, setting domestic records in their respective sectors
The Power of Aspiration.
Pulnovo Medical closes nearly $100 million Series C, setting a new Asia-Pacific record for medical device financing
A pioneer in China's original medical device innovation.
Pulnovo Medical Closes New Tens-of-Millions USD Funding Round to Accelerate Global Expansion
It secured a foothold in global markets and made substantial headway on multiple fronts in 2022.
The Gambler's Mirage in a Downturn: When a Fund Goes All-In on a Single Company
In the investment industry, it's as ubiquitous as air. When markets plunge, it also faces the greatest risk.
